Home β€Ί Stock analysis β€Ί EWTX

Edgewise Therapeutics (EWTX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)

Updated Oct 16, 2026, 4:00 PM ET

What changed since yesterday

EWTX dips 2.6% to $37.19. Closed at $37.19, -2.64% vs the prior close of $38.20. Day range $36.70–$38.28, opened at $38.28.

Last close$37.19-2.64%
Day range36.70–38.28
Open38.28
Volume1.14M
52-week range14.68–48.51
Avg volume (20d)1.65M

EWTX daily analysis β€” what happened

A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.

Oct 16, 2026 β€” EWTX dips 2.6% to $37.19
Oct 15, 2026 β€” EWTX jumps 3.2% to $38.20
Oct 14, 2026 β€” EWTX rises 2.0% to $37.02
Oct 13, 2026 β€” EWTX slides 5.6% to $36.28, a 3-month low, 7 down days in a row
Oct 12, 2026 β€” EWTX dips 1.6% to $38.45, a 1-month low, 6 down days in a row
Oct 9, 2026 β€” EWTX dips 0.4% to $39.06, a 1-month low, 5 down days in a row
Oct 8, 2026 β€” EWTX dips 0.9% to $39.23, 4 down days in a row
Oct 7, 2026 β€” EWTX dips 1.1% to $39.57, 3 down days in a row
Oct 6, 2026 β€” EWTX dips 0.7% to $40.02
Oct 5, 2026 β€” EWTX dips 2.7% to $40.30
Oct 2, 2026 β€” EWTX rises 2.3% to $41.40

EWTX latest news & SEC filings

Every SEC filing by or about EWTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Oct 2, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.

Source: SEC EDGAR filing 0001655016-26-000006

Aug 17, 2026 Β· Form 4/A β€” Insider trade (amended)

Amended insider trade report (Form 4/A)

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001705477-26-000002

Aug 17, 2026 Β· Form 4/A β€” Insider trade (amended)

Amended insider trade report (Form 4/A)

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001644087-26-000006

Aug 17, 2026 Β· Form 4/A β€” Insider trade (amended)

Amended insider trade report (Form 4/A)

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001853529-26-000003

Aug 17, 2026 Β· Form 4/A β€” Insider trade (amended)

Amended insider trade report (Form 4/A)

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001191702-26-000002

Aug 17, 2026 Β· Form 4/A β€” Insider trade (amended)

Amended insider trade report (Form 4/A)

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001853109-26-000002

Aug 14, 2026 Β· Form SCHEDULE 13G/A β€” Update to a passive 5%+ stake (13G)

Update to a passive 5%+ stake (13G)

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0001231919-26-000922

Aug 14, 2026 Β· Form SCHEDULE 13G/A β€” Update to a passive 5%+ stake (13G)

Update to a passive 5%+ stake (13G)

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0001104659-26-097206

Aug 14, 2026 Β· Form SCHEDULE 13G/A β€” Update to a passive 5%+ stake (13G)

Update to a passive 5%+ stake (13G)

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0001104659-26-097041

Aug 6, 2026 Β· Form SCHEDULE 13G β€” Passive stake (13G)

Passive stake (13G) β€” an investor reported owning more than 5%

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0000315066-26-001979

Aug 6, 2026 Β· Form 10-Q β€” Quarterly report

Quarterly report (unaudited financial statements for the quarter)

Quarter ended Jun 30, 2026:

Source: SEC EDGAR filing 0001104659-26-091670

Aug 6, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

This is a results-day filing: the earnings press release is attached as an exhibit.

Source: SEC EDGAR filing 0001104659-26-091671

Jul 16, 2026 Β· Form 8-K/A β€” Current report (amended)

Amended current report

Source: SEC EDGAR filing 0001104659-26-084088

Jul 13, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001104659-26-082902

Things to know before you trade EWTX

EWTX market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 16, 202638.2838.2836.7037.191.14M
Oct 15, 202637.6238.5337.2438.201.84M
Oct 14, 202635.9337.9435.6337.021.45M
Oct 13, 202638.1738.3536.0836.28810.10K
Oct 12, 202639.1239.3638.3238.451.54M
Oct 9, 202639.3040.4138.9339.061.06M
Oct 8, 202638.1439.4137.2439.231.36M
Oct 7, 202639.6641.0639.4039.571.45M
Oct 6, 202640.6641.0339.3440.021.62M
Oct 5, 202641.5541.7939.9840.301.63M
Oct 2, 202641.0141.9440.4241.401.46M
Oct 1, 202640.3941.4639.8640.481.29M
Sep 30, 202639.4942.1238.8940.601.68M
Sep 29, 202639.5339.5838.5139.191.92M
Sep 28, 202639.1240.1039.1239.792.98M
Sep 25, 202641.5941.9938.5739.342.49M
Sep 24, 202640.2841.9439.7441.161.38M
Sep 23, 202644.4144.4139.8241.052.61M
Sep 22, 202644.9945.9944.3944.512.09M
Sep 21, 202645.7045.9844.0944.641.18M

About Edgewise Therapeutics

Edgewise Therapeutics (EWTX) is listed on the Nasdaq and classified by the SEC under β€œPharmaceutical Preparations”. Its business address is in BOULDER, CO. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1710072.

EWTX board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
Laura BregeDirectorJun 17, 2026
Badreddin EdrisDirectorJun 16, 2026
Jonathan C FoxDirectorJul 1, 2026
Kevin KochPresident and CEOAug 14, 2026
Christopher Nathan MartinDirectorJun 16, 2026
Arlene MorrisDirectorJun 17, 2026
Jonathan D RootDirectorJul 17, 2026
Alan J RussellChief Scientific OfficerAug 17, 2026
Peter A. ThompsonDirectorJun 17, 2026

Executive officers

NameTitleLatest filing
Behrad DerakhshanChief Business OfficerAug 17, 2026
Joanne M. DonovanCMOAug 17, 2026
Kevin KochPresident and CEOAug 14, 2026
John R MooreGeneral CounselAug 17, 2026
Michael NofiChief Financial OfficerAug 17, 2026
Alan J RussellChief Scientific OfficerAug 17, 2026

Recent insider buys & sales

DateInsiderTypeSharesPrice
Aug 13, 2026Joanne M. DonovanSale2,919$43.41
Aug 13, 2026Joanne M. DonovanSale2,919$43.41
Aug 13, 2026Joanne M. DonovanSale2,919$43.41
Aug 13, 2026Joanne M. DonovanSale2,919$43.41
Aug 12, 2026Joanne M. DonovanSale800$44.52
Aug 12, 2026Joanne M. DonovanSale104$44.43
Aug 12, 2026Joanne M. DonovanSale2,779$43.71
Aug 12, 2026Joanne M. DonovanSale2,839$43.78
Aug 12, 2026Joanne M. DonovanSale800$44.52
Aug 12, 2026Joanne M. DonovanSale104$44.43
Aug 12, 2026Joanne M. DonovanSale2,779$43.71
Aug 12, 2026Joanne M. DonovanSale2,839$43.78
Aug 12, 2026Joanne M. DonovanSale800$44.52
Aug 12, 2026Joanne M. DonovanSale104$44.43
Aug 12, 2026Joanne M. DonovanSale2,779$43.71

EWTX financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
Dec 31, 2025β€”$-167.79M-1.63$-143.82M
Dec 31, 2024β€”$-133.81M-1.45$-109.03M
Dec 31, 2023β€”$-100.16M-1.57$-91.95M
Dec 31, 2022β€”$-67.64M-1.26$-52.63M
Dec 31, 2021β€”$-42.81M-1.14$-33.51M

Latest balance sheet: total assets $479.69M, total liabilities $31.61M, cash $72.32M (as of Jun 30, 2026).

EWTX earnings / results-day log

DateFilingClose that day
Aug 6, 20268-K Item 2.02 (results)$44.42
May 7, 20268-K Item 2.02 (results)$35.58
Feb 26, 20268-K Item 2.02 (results)$29.66
Nov 6, 20258-K Item 2.02 (results)$17.09
Aug 7, 20258-K Item 2.02 (results)$12.95
May 8, 20258-K Item 2.02 (results)$14.70
Mar 3, 20258-K Item 2.02 (results)$25.53
Nov 7, 20248-K Item 2.02 (results)$35.43
Aug 8, 20248-K Item 2.02 (results)β€”
May 9, 20248-K Item 2.02 (results)β€”
Feb 22, 20248-K Item 2.02 (results)β€”
Jan 19, 20248-K Item 2.02 (results)β€”

Related stocks Β· Pharmaceutical Preparations

Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)

Popular today

Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)

More on EWTX

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.